Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Conventional Measurements of OLTS with CT Grossly Overestimate the Size of Lesions

When orthopedic surgeons attempt to evaluate and manage osteochondral lesions of the talus (OLTs) using conventional computed tomography (CT), they may overestimate their size. This, in turn, influences treatment strategies. Therefore, OLTs often warrant advanced imaging studies, especially in revision or cases with cystic defects. To determine the effectiveness of these techniques, a study, “Value…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

When orthopedic surgeons attempt to evaluate and manage osteochondral lesions of the talus (OLTs) using conventional computed tomography (CT), they may overestimate their size. This, in turn, influences treatment strategies. Therefore, OLTs often warrant advanced imaging studies, especially in revision or cases with cystic defects. To determine the effectiveness of these techniques, a study, “Value of 3D Reconstructions of CT Scans for Calcaneal Fracture Assessment,” was performed by Foot & Ankle International (FAI).

Understanding the True Anatomy and Size of OLTs May Help Guide Treatment

OLTs are defined as localized irregularities in the articular chondral surface also involving the subchondral bone. The exact cause of these lesions is unclear, but they are likely the result of a rotational ankle injury, such as a ligamentous sprain or bony fracture. OLTs are a common issue in orthopedic medicine; however, treatment remains a clinical challenge.

Most OLTs can initially be managed with nonoperative treatment. When this approach fails, surgery is often indicated. Surgical intervention depends on the chronicity of the lesion, size of the lesion, presence of cystic lesions, and the stability of the cartilage.

Many procedures for larger lesions require autograft or allograft tissue to fill the void, but these procedures can be very costly and do not always address the problem effectively. Understanding the true anatomy and size of these lesions may help better guide treatment, allowing for accurate preoperative planning and potential cost savings.

Conventional CT Scans Overestimate OLT Size

The results of the FAI study showed that conventional measurements of OLTs with CT scans grossly overestimated the size of the lesion. The average approximate OLT volumes from 10 independent observer CT measurements comprised of a rectangular prism (Vrec), a right cylinder (Vcyl), and right cone (Vcone) were compared to morphometric true-volume (MTV) via 3D reconstruction. On average, the Vrec, Vcyl, and Vcone estimates were 303%, 864%, and 285% greater, respectively, than the MTV. The FAI study demonstrates that volume measurements of OLTs using conventional CT typically overestimate true-volume approximations when compared to OLTs created with 3D reconstructions.

CurveBeam Imaging Provides Valuable Insights to Orthopedic Surgeons

3D reconstructions of CT scans are used frequently in orthopedic surgery; however, the usefulness of this technique in OLTs has not been reported in the literature. 3D CT scans, such as those created using CurveBeam Cone Beam CT imaging technology, provide insight previously unavailable through either 2D and plain radiography. These detailed images, like those seen below, provide more precise measurements that can assist surgeons in both accurate diagnosing and preoperative planning.

Bilateral – Talar Head Exposed Sharp Filter: CubeVue, CurveBeam’s custom visualization software, can segment a volume to reveal joint surfaces, such as the talar head.

Talus Navicular Cluster: CurveBeam’s proprietary segmentation tools (under development) are demonstrated here using third-party viewing software.

CurveBeam designs and manufactures Cone Beam CT imaging equipment for the orthopedic and podiatric specialties. CurveBeam’s pedCAT system and CubeVue custom visualization software have been installed in facilities across the United States, Europe, Australia, and China. More recently, CurveBeam’s InReach system, a multi-extremity CT optimized for hand, wrist, and elbow imaging, and LineUP system, a weight-bearing multi-extremity CT for imaging of the foot, ankle, and knee, have been added to the product line. Today, CurveBeam Cone Beam CT scans are setting new standards in orthopedic 3D imaging worldwide.

To find out more, visit https://www.curvebeam.com/about/about-curvebeam/

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512